| Full project title: | PRISM - Psychiatric Ratings using Intermediate Stratified Markers |
| Start date: | 1 April 2016 |
| Duration: | 3 years (2016 – 2019) |
| Estimated costs: | € 16.5 million |
| Project coordinator: | University of Groningen, Netherlands Prof Dr Martien Kas |
| Project leader: | Eli Lilly and Company Ltd Dr Hugh Marston |
| Funding: | Innovative Medicines Initiative 2 Joint Undertaking: European Union’s Horizon 2020 research and innovation programme and EFPIA |
Innovative Medicine Initiative (IMI) is Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.
